SAN DIEGO, July 20, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that it and its subsidiary HempMeds® Brasil garnered extensive media coverage across Brazil about the Company’s growth and the booming cannabis market across U.S. and Latin America.
A July 16, 2017 article from Rio de Janeiro-based Brazilian newspaper O Globo “Negócios que dão a maior onda”, or “In the cannabis market, these businesses will get you high”, which was picked up by several other major news outlets across the Country, discussed the explosive growth projected for the cannabis market in the U.S. and Latin America and recent advances in legislation. The article also featured a global AFP photo of Medical Marijuana, Inc.’s products taken at the 4th Annual Cannabis World Congress and Business Expo in New York City in June 2017.
“It’s encouraging to see the widespread global media coverage of the medical marijuana and CBD markets; we are always pleased to be at the forefront of discussion of one of the fastest growing industries in the world,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “A goal of our company has been to provide an alternative health-and-wellness approach to those who may fail conventional medical treatment.”
“Brazil, a nation willing to challenge convention and explore botanical remedies that may provide health-and-wellness benefits, has set forth progress in terms of botanical cannabinoids – and many Brazil-national families have seen the benefits. We appreciate that the recent press coverage is helping educate the people of Brazil and the world,” added Dr. Titus.
HempMeds Brasil™ is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company’s hemp CBD oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO™ for any condition and HempMeds Brasil™ has worked with several cases including patients suffering from:
- Amyotrophic Lateral Sclerosis
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically-sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson’s, Chronic Pain, Psoriasis, Cancer, Alzheimer’s, Diabetes, ALS, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer